Poltreg Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes
PolTREG has dosed the first patient in a Phase 2 trial of PTG-007, an autologous cell therapy for pre-symptomatic...
Jon Napitupulu
Sonnet Biotherapeutics Expands Ovarian Cancer Dose Escalation Trial
Sonnet BioTherapeutics reports two out of three patients with platinum-resistant ovarian cancer (PROC) achieved a partial response (PR) in...
Clearmind Medicine Gets IRB Approval for Alcohol Use Disorder Trial
Clearmind Medicine has received Institutional Review Board (IRB) approval from Hadassah Medical Center in Jerusalem for its ongoing Phase...
Aptose Begins 160 mg Tuspetinib Dosing in Tuscany Trial
Aptose Biosciences’ Phase 1/2 TUSCANY trial of tuspetinib (TUS) in combination with venetoclax and azacitidine (VEN/AZA) has cleared the...
Distalmotion Enrolls Dexter® System Trials for Surgery and Gynecology
Distalmotion has reached key enrollment milestones in two US pivotal trials for its DEXTER robotic surgery system: RAVEN for...
Arch Biopartners Doses First Patient in LSALT Peptide Trial
Arch Biopartners has dosed the first patient at Toronto General Hospital in its Phase 2 trial of LSALT peptide...
BioCardia Updates on CardiAMP® and Helix™ Regulatory Timelines
BioCardia is pursuing a two-pronged regulatory strategy in Q3/Q4 2025, seeking FDA approval for its Helix transendocardial delivery catheter...
Praxis Precision Medicines Announces Positive Topline Results in Seizure Study
Praxis Precision Medicines announced positive topline data from the Phase 2 RADIANT study of vormatrigine in focal onset seizures....
Simufilam Shows Promise in Preclinical TSC-Related Epilepsy Study
Cassava Sciences reports positive preclinical data for simufilam in a tuberous sclerosis complex (TSC) mouse model, specifically demonstrating anti-seizure...
Microbiotica Completes Phase 1b Ulcerative Colitis Trial Recruitment
Microbiotica has completed patient enrollment in its Phase 1b COMPOSER-1 trial of MB310, a live biotherapeutic product (LBP) for...